Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8806 |
High Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.8692 |
High Similarity |
NPD422 |
Phase 1 |
0.8652 |
High Similarity |
NPD3750 |
Approved |
0.85 |
High Similarity |
NPD1551 |
Phase 2 |
0.8433 |
Intermediate Similarity |
NPD1203 |
Approved |
0.8406 |
Intermediate Similarity |
NPD1240 |
Approved |
0.838 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8345 |
Intermediate Similarity |
NPD6799 |
Approved |
0.831 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.831 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8298 |
Intermediate Similarity |
NPD3748 |
Approved |
0.8296 |
Intermediate Similarity |
NPD2797 |
Approved |
0.8289 |
Intermediate Similarity |
NPD3749 |
Approved |
0.8288 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8286 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8222 |
Intermediate Similarity |
NPD3225 |
Approved |
0.8209 |
Intermediate Similarity |
NPD9717 |
Approved |
0.82 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.8194 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.8176 |
Intermediate Similarity |
NPD920 |
Approved |
0.8169 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8138 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.8129 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.8129 |
Intermediate Similarity |
NPD3268 |
Approved |
0.8125 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8116 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.8112 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.8106 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8105 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.8105 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8105 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8074 |
Intermediate Similarity |
NPD1481 |
Phase 2 |
0.8069 |
Intermediate Similarity |
NPD1243 |
Approved |
0.8052 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8042 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.8041 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.8041 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.8014 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.8013 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.8 |
Intermediate Similarity |
NPD1535 |
Discovery |
0.8 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7986 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7974 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7974 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7974 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7973 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7961 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7945 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7933 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7919 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7919 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7919 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7919 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7917 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7908 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7908 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7905 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.7899 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7899 |
Intermediate Similarity |
NPD3267 |
Approved |
0.7891 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7872 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7868 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7867 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7857 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7857 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7857 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7857 |
Intermediate Similarity |
NPD1008 |
Clinical (unspecified phase) |
0.7836 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7836 |
Intermediate Similarity |
NPD1894 |
Discontinued |
0.7832 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7832 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7832 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7832 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7832 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7821 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.781 |
Intermediate Similarity |
NPD1608 |
Approved |
0.7808 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7808 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7806 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7806 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7793 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7778 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7764 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7762 |
Intermediate Similarity |
NPD4307 |
Phase 2 |
0.775 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7746 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7746 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD1241 |
Discontinued |
0.7716 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7716 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7714 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.7712 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7708 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7707 |
Intermediate Similarity |
NPD6971 |
Discontinued |
0.7703 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD4288 |
Approved |
0.7692 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7692 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7687 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7683 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7625 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7625 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7622 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7622 |
Intermediate Similarity |
NPD411 |
Approved |
0.7616 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7606 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.76 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7591 |
Intermediate Similarity |
NPD17 |
Approved |
0.7586 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7582 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7568 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7568 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7568 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7568 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7566 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7564 |
Intermediate Similarity |
NPD37 |
Approved |
0.7547 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7547 |
Intermediate Similarity |
NPD919 |
Approved |
0.7535 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7532 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7532 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7519 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7517 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7517 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7515 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD6100 |
Approved |
0.75 |
Intermediate Similarity |
NPD5494 |
Approved |
0.75 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7485 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7453 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7448 |
Intermediate Similarity |
NPD4062 |
Phase 3 |
0.7434 |
Intermediate Similarity |
NPD7440 |
Discontinued |
0.7425 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7419 |
Intermediate Similarity |
NPD1653 |
Approved |
0.741 |
Intermediate Similarity |
NPD3847 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7394 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7394 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7385 |
Intermediate Similarity |
NPD9697 |
Approved |
0.7383 |
Intermediate Similarity |
NPD4476 |
Approved |
0.7383 |
Intermediate Similarity |
NPD4477 |
Approved |
0.7362 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7361 |
Intermediate Similarity |
NPD2614 |
Approved |
0.7357 |
Intermediate Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.7349 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7349 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7346 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7338 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7324 |
Intermediate Similarity |
NPD1283 |
Approved |
0.731 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.731 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7305 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7303 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7301 |
Intermediate Similarity |
NPD5710 |
Approved |
0.7301 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7292 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.729 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7279 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7279 |
Intermediate Similarity |
NPD943 |
Approved |
0.7267 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7262 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7261 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD2354 |
Approved |
0.7255 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7254 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7239 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7237 |
Intermediate Similarity |
NPD2654 |
Approved |
0.723 |
Intermediate Similarity |
NPD4622 |
Approved |
0.723 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD1184 |
Approved |
0.723 |
Intermediate Similarity |
NPD4618 |
Approved |
0.7229 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7222 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7219 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7219 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7203 |
Intermediate Similarity |
NPD1876 |
Approved |
0.7197 |
Intermediate Similarity |
NPD968 |
Approved |
0.7197 |
Intermediate Similarity |
NPD2370 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD3134 |
Approved |
0.7188 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7183 |
Intermediate Similarity |
NPD3972 |
Approved |
0.7183 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7179 |
Intermediate Similarity |
NPD5049 |
Phase 3 |
0.7171 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7161 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1537 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1519 |
Approved |
0.7152 |
Intermediate Similarity |
NPD1538 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD1358 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5585 |
Approved |
0.7143
|
Intermediate Similarity |
NPD9265 |
Clinical (unspecified phase) |